Overview

The APS and APS Psychology and Psychedelic-Assisted Therapy Interest Group hosts this live panel discussion with experts and professionals, to discuss the recent decision of the Therapeutic Goods Administration (TGA).

In February 2023, the TGA declared that starting July 1, 2023, psilocybin and MDMA will be eligible for prescription by certified psychiatrists for the treatment of selected mental health conditions. 

The panel, facilitated by APS Psychedelic-Assisted Therapy Interest Group convenor Professor James Bennett-Levy, discusses the:

• TGA rescheduling decision,

• implications of the decision for the implementation of psychedelic-assisted psychotherapy in clinical settings, and 

• implications of the decision for psychologists who may wish to work in psychedelic-assisted psychotherapy contexts.

Questions will be posed to the panel by Professor Bennett-Levy and then questions will be sought from the live audience.

Level of Learning

Foundational. This activity is targeted to those new to the topic.

Duration of access

Access to the recording and presenter slides is for 12 months from the date of confirmed registration.

APS CPD-Approved

This activity has been assessed against the APS Standards for CPD activities and approved for its education quality. Learn more about the APS CPD Approval process

CPD Frequently Asked Questions

Refer to the APS CPD Frequently Asked Questions for general and technical information when undertaking APS Professional development activities.

Activity details 

• On-demand webinar recording 

Learning Outcomes

Upon completion of this activity, participants should be able to:

• outline the TGA rescheduling decision,

• describe implications of the decision for the implementation of psychedelic-assisted psychotherapy in clinical settings and,

• describe the implications of the decision for psychologists who may wish to work in psychedelic-assisted psychotherapy contexts.

Presenter(s)

Panel

About the presenter(s)

The following panel members are now confirmed:
Professor Robyn Langham, Chief Medical Advisor TGA
Professor Richard Harvey, Chair Steering Group for Psychedelic-assisted Therapy, RANZCP
Dr. Catriona Davis-McCabe President, APS
Dr. Zena Burgess, CEO APS
Dr Lara Bertolino, Clinical Psychologist and Committee Member of APS PAT Interest Group